Phase Ib Efficacy, Safety of Anti-CD47 Antibody Magrolimab + Azacitidine in Untreated AML

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
The combination of magrolimab plus azacytidine was associated with rapid, deep responses with little added toxicity, including in patients with the TP53 mutation.
Format: Microsoft PowerPoint (.ppt)
File Size: 475 KB
Released: December 7, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

Addition of venetoclax to lenalidomide and rituximab in untreated MCL was well tolerated, showed preliminary anticancer efficacy, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue